MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.47
-1.34
-11.35%
After Hours: 10.46 -0.01 -0.10% 19:59 02/25 EST
OPEN
11.09
PREV CLOSE
11.81
HIGH
11.64
LOW
10.37
VOLUME
7.84M
TURNOVER
--
52 WEEK HIGH
12.90
52 WEEK LOW
1.580
MARKET CAP
1.85B
P/E (TTM)
-13.7042
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Biocryst - Receives Positive CHMP Opinion For Orladeyo An Oral, Once-Daily Therapy To Prevent Attacks In Patients With Hereditary Angioedema
reuters.com · 3h ago
BioCryst's ORLADEYO nabs CHMP positive recommendation in hereditary angioedema
BioCryst Pharmaceuticals (BCRX) announces that the Committee for Medicinal Products for Human Use ((CHMP)) of the European Medicines Agency ((EMA)) has adopted a positive opinion recommending the approval of ORLADEYO (berotralstat) for routine
Seekingalpha · 4h ago
BioCryst Receives Positive CHMP Opinion for ORLADEYO(TM) (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- For investors and media only RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2021 (GLOBE...
GlobeNewswire · 4h ago
DJ BioCryst Pharmaceuticals, Inc. CEO Jon Stonehouse on Q4 2020 Results -- Earnings Call Transcript >BCRX
Dow Jones · 8h ago
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
Zacks.com · 11h ago
TDOC, EDIT among premarket gainers
IT Tech Packaging (ITP) -23% on stock offering.Ping Identity Holding (PING) -14% on Q4 results.ReTo Eco-Solutions (RETO) -10%.United States Antimony (UAMY) -9%.BioCryst Pharmaceuticals (BCRX) -9% on Q4 earnings.Best Buy (BBY) -7% on Q4 results.Chimerix
Seekingalpha · 12h ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 12h ago
8-K: BIOCRYST PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- 0000882796 False 0000882796 2021-02-25 2021-02-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 13h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCRX. Analyze the recent business situations of BioCryst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCRX stock price target is 13.50 with a high estimate of 16.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 274
Institutional Holdings: 129.55M
% Owned: 73.37%
Shares Outstanding: 176.57M
TypeInstitutionsShares
Increased
58
12.60M
New
52
3.52M
Decreased
53
21.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Robert Ingram
Chief Executive Officer/President/Director
Jon Stonehouse
Chief Financial Officer/Senior Vice President
Anthony Doyle
Senior Vice President/Secretary
Alane Barnes
Senior Vice President
Yarlagadda Babu
Senior Vice President
Charles Gayer
Senior Vice President
William Sheridan
Senior Vice President
Megan Sniecinski
Director
Sanj Patel
Chief Accounting Officer
Michael Jones
Vice President/General Manager
Allen Hodge
Independent Director
George Abercrombie
Independent Director
Stephen Aselage
Independent Director
Theresa Heggie
Independent Director
Nancy Hutson
Independent Director
Kenneth Lee
Independent Director
Alan Levin
Independent Director
Helen Thackray
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.